Skip to main content

Advertisement

SpringerLink
Log in

Outcome Data of Patients with Peritoneal Carcinomatosis from Gastric Origin Treated by a Strategy of Bidirectional Chemotherapy Prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in a Single Specialized Center in Japan

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Management of peritoneal disseminated gastric cancer (GC) remains a challenging problem. The purpose of our study was to evaluate the outcome of bidirectional induction chemotherapy [bidirectional intraperitoneal and systemic induction chemotherapy (BIPSC)] in patients with peritoneal carcinomatosis (PC) arising from GC who underwent cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Patients and Methods

Overall, 194 patients with PC arising from GC were treated with BIPSC comprising intraperitoneal docetaxel at a dose of 20 mg/m2 and cisplatin at a dose of 30 mg/m2 followed by four cycles of oral S-1 at a dose of 60 mg/m2. CRS and HIPEC were performed in responders to BIPSC.

Results

Of these 194 patients, 152 (78.3 %) underwent CRS and HIPEC between January 2005 and December 2012. Treatment-related mortality was 3.9 %, and major complications occurred in 23.6 % of patients. The median survival rate was 15.8 months, with 1-, 2-, and 5-year survival rates of 66, 32 and 10.7 %, respectively, in the patients treated with combined treatment. Multivariate analysis identified pathologic response to BIPSC (p = 0.001), low tumor burden [peritoneal cancer index (PCI) ≤ 6] (p = 0.001), and completeness of CRS (CC-0, CC-1) (p = 0.001) as independent predictors for a better prognosis.

Conclusion

As a viable option, BIPSC with CRS and HIPEC for patients with PC arising from GC may be performed safely, with acceptable morbidity and mortality, in a specialized unit. Response to BIPSC, optimal CRS and limited peritoneal dissemination seem to be essential to achieve the best outcomes in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynaecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.

    Article  CAS  PubMed  Google Scholar 

  2. Bozzetti F, Yu W, Baratti D, Kusamura S, Deraco M. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol. 2008;98:273–6.

    Article  CAS  PubMed  Google Scholar 

  3. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163–8.

    Article  CAS  PubMed  Google Scholar 

  4. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24:2903–3909.

    Article  CAS  PubMed  Google Scholar 

  5. Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and hemohyperthermic peritoneal perfusion. Br J Surg. 2005;92:370–5.

    Article  CAS  PubMed  Google Scholar 

  6. Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004; 139:20–6.

    Article  CAS  PubMed  Google Scholar 

  7. Hall JJ, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg. 2004; 8:454–463.

    Article  PubMed  Google Scholar 

  8. Yonemura Y, Bandou E, Sawa T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32:661–65.

    Article  CAS  PubMed  Google Scholar 

  9. Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol. 2009;100:311–16.

    Article  CAS  PubMed  Google Scholar 

  10. Yonemura Y, Elnemr A, Endou Y, Ishibashi H, Mizumoto A, Miura M, et al. Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol. 2012;2012:148420.

    PubMed Central  PubMed  Google Scholar 

  11. Okabe H, Ueda S, Obama K, Hosogi H, Sakai Y. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol. 2009;16:3227–36.

    Article  PubMed  Google Scholar 

  12. Fujiwara Y, Takiguchi S, Nakajima K, et al. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination. Ann Surg Oncol. 2011;18:3726–31.

    Article  PubMed  Google Scholar 

  13. Imano M, Yasuda A, Itoh T, et al. Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. J Gastrointest Surg. 2012;16:2190–6.

    Article  PubMed  Google Scholar 

  14. Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res. 1996;82:235–53.

    Article  CAS  PubMed  Google Scholar 

  15. White SK, Stephens AD, Sugarbaker PH. Hyperthermic intraoperative intraperitoneal chemotherapy safety considerations. AORN J. 1996;63:716–24.

    Article  CAS  PubMed  Google Scholar 

  16. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49–68.

    Google Scholar 

  17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2009;92:205–16.

    Article  Google Scholar 

  18. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–112.

    Article  Google Scholar 

  19. Badgwell B, Cornier JN, Krishnan S, et al. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol. 2008;15:2684–91.

    Article  PubMed  Google Scholar 

  20. Lorenzen S, Panzram B, Rosenberg R, et al. Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection. Ann Surg Oncol. 2010;17:2733–9.

    Article  PubMed  Google Scholar 

  21. Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitonel hyperthermic chemoperfusion combined with surgery. Cancer. 1997;79:884–91.

    Article  CAS  PubMed  Google Scholar 

  22. Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004;139:20–6.

    Article  CAS  PubMed  Google Scholar 

  23. Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer withperitoneal metastasis. Ann Oncol. 2010;21:67–70.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NPO to Support Peritoneal Dissemination Treatment, Department of General Surgery, Tokushu-Kai Hospital, Kishiwada, Osaka, Japan

    Emel Canbay MD, PhD, Shouzou Sako MD, PhD & Yutaka Yonemura MD, PhD

  2. Department of General Surgery, Kusatsu General Hospital, Kusatsu, Japan

    Akiyoshi Mizumoto MD, PhD, Masumi Ichinose MD, PhD, Haruaki Ishibashi MD, PhD, Masamitsu Hirano MD, PhD, Nobuyuki Takao MD, PhD & Yutaka Yonemura MD, PhD

  3. Department of General Surgery, Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan

    Yutaka Yonemura MD, PhD

Authors
  1. Emel Canbay MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akiyoshi Mizumoto MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masumi Ichinose MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Haruaki Ishibashi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shouzou Sako MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masamitsu Hirano MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nobuyuki Takao MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yutaka Yonemura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emel Canbay MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Canbay, E., Mizumoto, A., Ichinose, M. et al. Outcome Data of Patients with Peritoneal Carcinomatosis from Gastric Origin Treated by a Strategy of Bidirectional Chemotherapy Prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in a Single Specialized Center in Japan. Ann Surg Oncol 21, 1147–1152 (2014). https://doi.org/10.1245/s10434-013-3443-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-013-3443-2

Keywords

Search

Navigation